Reabetswe Sebatana

Ms. Reabetswe Sebatana

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RSReabetswe Sebatana
Reabetswe Sebatana
KKKudzai Daisy Kahwenga
Kudzai Daisy Kahwenga
AMAllan Nyasha Magura
Allan Nyasha Magura
AMAmanda Mdlophane
Amanda Mdlophane
JZJan Rijn Zeevaart
Jan Rijn Zeevaart
Bwalya Angel WitikaBwalya Angel Witika
Bwalya Angel Witika
Atherosclerosis is a chronic progressive disease which is known to cause acute cardiovascular events as well as cerebrovascular events with high mortality. Unlike many other diseases, atherosclerosis is often diagnosed only after an acute or fatal event. At present, the clinical problems of atherosclerosis mainly involve the difficulty in confirming the plaques or identifying the stability of the plaques in the early phase. In recent years, the development of nanotechnology has come with various advantages including non-invasive imaging enhancement, which can be studied for the imaging of atherosclerosis. For targeted imaging and atherosclerosis treatment, nanoliposomes provide enhanced stability, drug administration, extended circulation, and less toxicity. This review discusses the current advances in the development of tailored liposomal nano-radiopharmaceutical-based techniques and their applications to atherosclerotic plaque diagnosis. This review further highlights liposomal nano-radiopharmaceutical localisation and biodistribution—key processes in the pathophysiology of atherosclerosis. Finally, this review discusses the direction and future of liposomal nano-radiopharmaceuticals as a potential clinical tool for the assessment and diagnosis of atherosclerotic plaque.